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Interleukin-12 (IL12) is a cytokine that is secreted by activated phagocytes and dendritic cells and that induces
interferon-g production by natural-killer and T lymphocytes. It consists of two subunits, p35 and p40, which are
encoded by IL12A and IL12B, respectively. The first reported patient with a genetic cytokine disorder was a Pakistani
child, who was homozygous for a large loss-of-function deletion (g.482+82_856–854del) in IL12B.This IL12-deficient
child suffered from infections caused by bacille Calmette-Gue´rin (BCG) and Salmonella enteritidis. We herein report
12 additional patients from five other kindreds. In one kindred from India, the same large deletion that was described
elsewhere (g.482+82_856–854del) was identified. In four kindreds from Saudi Arabia, a recessive loss-of-function
frameshift insertion (g.315_316insA) was found. A conserved haplotype encompassing the IL12B gene suggested that
a founder effect accounted for the recurrence of each mutation. The two founder mutational events—
g.482+82_856–854del and g.315_316insA—were estimated to have occurred ∼700 and ∼1,100 years ago, respectively.
Among a total of 13 patients with IL12 deficiency, 1 child had salmonellosis only and 12 suffered from clinical disease
due to BCG or environmental nontuberculous mycobacteria. One patient also had clinical disease caused by virulent
Mycobacterium tuberculosis, five patients had clinical disease caused by Salmonella serotypes, and one patient had
clinical disease caused by Nocardia asteroides. The clinical outcome varies from case to case, since five patients (aged
2–11 years) died of overwhelming infection, whereas eight patients (aged 3–12 years) are still in good health and are
not currently taking antibiotics. In conclusion, IL12 deficiency is not limited to a single kindred, shows significant
variability of outcome, and should be considered in the genetic diagnosis of patients with mycobacteriosis and/or
salmonellosis. To date, two founder IL12B mutations have been identified, accounting for the recurrence of a large
deletion and a small insertion within populations from the Indian subcontinent and from the Arabian Peninsula,
respectively.
Introduction
Patients with Mendelian susceptibility to mycobacterial
disease (MIM 209950) (McKusick 1998) are vulnerable
to poorly virulent mycobacterial species—such as bacille
Calmette-Gue´rin (BCG) vaccines (Casanova et al. 1995,
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1996) and environmental nontuberculous mycobacteria
(NTM) (Levin et al. 1995; Frucht and Holland 1996).
They are also vulnerable to the more virulent speciesMy-
cobacterium tuberculosis, the agent of tuberculosis
(Jouanguy et al. 1997; Altare et al. 2001). Other infectious
diseases occur rarely in these patients—with the exception
of salmonellosis, which affects almost half of the patients.
Most sporadic and familial cases are suggestive of auto-
somal recessive inheritance (Levin et al. 1995; Casanova
et al. 1996); however, in some families, the syndrome
segregates in an autosomal dominant (Jouanguy et al.
1999; Dupuis et al. 2001) or X-linked recessive (Frucht
and Holland 1996; Frucht et al. 1999) pattern. Genetic
heterogeneity is further suggested by histopathological
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Figure 1 Pedigrees of six families with IL12 deficiency caused
by IL12B mutations. Each kindred is designated by a capital letter
(A–F), each generation is designated by a roman numeral (I or II), and
each individual is designated by an arabic numeral (1–8). Patients with
mycobacteriosis and/or salmonellosis are represented by black sym-
bols. The probands are indicated by arrows. “E?” indicates individuals
for whom genetic analysis was not possible (e.g., B.II.1, who died of
disseminated BCG infection at age 5 years).
and clinical phenotypic heterogeneity (Emile et al. 1997).
Some patients die of overwhelming mycobacterial disease
with lepromatous-like lesions in early childhood, whereas
other patients develop, later in life, disseminated but cur-
able infections with tuberculoid granulomas.
Five disease-causing autosomal genes (IFNGR1,
IFNGR2, STAT1, IL12RB1, and IL12B) have been
found, and a further degree of allelic heterogeneity ac-
counts for the existence of nine defined disorders. Al-
though genetically different, these disorders are physio-
logically related, as all result in impaired interferon-g
(IFNg)–mediated immunity. IFNg is a cytokine produced
by natural-killer (NK) and T lymphocytes that binds to
a heterodimeric ubiquitous receptor. Null recessive
mutations in IFNGR1 are responsible for complete
IFNg-receptor ligand-binding–chain (IFNgR1) defi-
ciency. These mutations abolish either receptor ex-
pression (Jouanguy et al. 1996; Newport et al. 1996;
Pierre-Audigier et al. 1997; Altare et al. 1998b; Holland
et al. 1998; Roesler et al. 1999; Cunningham et al.
2000) or the binding of surface-expressed receptors to
IFNg (Jouanguy et al. 2000; Allende et al. 2001). Partial
recessive (Jouanguy et al. 1997) and dominant (Jouan-
guy et al. 1999; Villella et al. 2001) IFNgR1 deficiencies
have also been described. Different recessive mutations
in IFNGR2 are responsible for complete (Dorman and
Holland 1998; Dorman et al. 2000) or partial (Do¨ffin-
ger et al. 2000) IFNg signaling-chain (IFNgR2) defi-
ciency. We also recently identified a dominant mutation
in STAT1, resulting in a partial signal transducer and
activator of transcription–1 (STAT1) deficiency and in
impaired cellular responses to IFNg (Dupuis et al. 2001).
Finally, two other genetic defects result in normal
cellular responses to IFNg but in abnormal interleukin-
12 (IL12)–dependent production of IFNg. Null reces-
sive mutations have been identified in IL12RB1, which
encodes the IL12-receptor b1 subunit (IL12Rb1) that is
expressed on NK and T cells (Altare et al. 1998a; de
Jong et al. 1998; Verhagen et al. 2000; Aksu et al. 2001;
Altare et al. 2001; Sakai et al. 2001). As do patients
with partial IFNgR1, IFNgR2, and STAT1 deficiency,
patients with complete IL12Rb1 deficiency have a
milder clinical phenotype than do patients with com-
plete IFNgR1 and IFNgR2 deficiency, probably owing
to residual IFNg-mediated immunity (Dupuis et al.
2000). Whereas a number of patients with IL12Rb1
deficiency have been reported, only one child has been
found to carry a null homozygous large deletion in
IL12B, which encodes the p40 subunit of IL12 (Altare
et al. 1998c). IL12 is a heterodimeric cytokine (p70),
comprising two subunits, p35 and p40, which is ex-
pressed by activated phagocytes and dendritic cells
(Trinchieri 1998). To date, IL12 deficiency is the only
human inherited cytokine disorder known. In this study,
we investigated whether IL12 deficiency could be de-
tected in other patients and, if so, whether it can be
used to describe the pathogenic IL12B mutations in-
volved and the associated clinical phenotypes.
Subjects and Methods
Subjects and Kindreds
Kindred A.—The parents are consanguineous, origi-
nating from Pakistan and currently living in the United
Kingdom (fig. 1 and table 1). The proband (A.II.1) suf-
fered from BCG and Salmonella enteritidis infectious
diseases at the ages of 3 mo and 3.5 years, respectively.
She has been diagnosed with IL12 deficiency and is now
10 years old and well, with no current treatment (Altare
et al. 1998c).
Kindred B.—The parents are first cousins, originating
from the Gujarat region of India and currently living in
Singapore. Their first daughter (B.II.1) was inoculated
with BCG at birth and died at age 5 years, of dissemi-
nated BCG infection (Murugasu et al. 1988). A lymph-
node biopsy showed tuberculoid granulomas with mul-
tiple visible acid-fast bacilli. Her brother (B.II.2), who
was also vaccinated with BCG, suffered no adverse ef-
fects and is now a healthy 15 year old. The youngest
sister (B.II.3) was not vaccinated with BCG. At age 2–-
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Table 1
Clinical Phenotype of Patients with IL12 Deficiency
PATIENT MUTATION
PLACE OF
ORIGINa
ALIVE AT
FOLLOW-
UP?
AGEb
(years)
BACTERIAc
BCG NTM Mtb Other
A.II.1 g.48282_856–854del Pakistan Yes 11 D, R … … S. enteritidis
B.II.1 Not done India No 5 D, R … … …
B.II.3 g.48282_856–854del India Yes 10 … … … S. enteritidis
C.II.1 Not done Saudi Arabia No 2 D, R … … …
C.II.2 g.315_316insA Saudi Arabia Yes 10 D … … N. asteroides
C.II.3 g.315_316insA Saudi Arabia Yes 3 D … … …
D.II.1 g.315_316insA Saudi Arabia Yes 11 L … … …
D.II.2 g.315_316insA Saudi Arabia Yes 10 L … … …
D.II.4 g.315_316insA Saudi Arabia Yes 6 L … L S. paratyphi C
E.II.2 g.315_316insA Saudi Arabia No 2 D, R … … …
F.II.3 g.315_316insA Saudi Arabia No 11 D … … Salmonella
F.II.4 g.315_316insA Saudi Arabia Yes 12 D … … …
F.II.5 g.315_316insA Saudi Arabia No 5 … D, R … Salmonella group B
a Patient A.II.1 has been reported by Altare et al. (1998c), and patient B.II.1 has been reported by Murugasu et al. (1988).
b At death or last follow-up, at the time of preparation of the manuscript of this report.
c Mtb p M. tuberculosis. D p disseminated; R p recurrent; L p local. “Salmonella” denotes that serotype has not
been determined.
4 years, she suffered four episodes of disseminated S.
enteritidis infection, all of which responded to antibi-
otics. She is now 9 years old and well, with no current
treatment.
Kindred C.—The parents are first cousins, originating
from and living in Saudi Arabia. Their first child (C.II.1)
was inoculated with BCG at birth and died from dis-
seminated BCG infection at age 2 years. Their second
child (C.II.2) was vaccinated with BCG shortly after
birth and developed disseminated BCG infection.
Lymph-node biopsy showed mature granuloma forma-
tion and multiple acid-fast bacilli. This child responded
very well to antimycobacterial drugs. She presented No-
cardia asteroides pleurisy at age 8 years and again re-
sponded well to antibiotics. The patient is now 9 years
of age, in good health, and not taking medication. The
proband (C.II.3) was vaccinated with live BCG at birth
and developed disseminated BCG infection 6 mo later.
A lymph-node biopsy showed no mature granuloma for-
mation and multiple acid-fast bacilli. She responded well
to antimycobacterial therapy and is now a healthy 2-
year-old. The last child (C.II.4) was not vaccinated with
live BCG and is currently a healthy 1-year-old.
Kindred D.—The parents are first cousins, originating
from and living in Saudi Arabia. The proband (D.II.1)
was vaccinated with BCG at birth and presented axillary
BCG adenitis at age 14 mo. He was treated with anti-
biotics and by surgical excision. His brother (D.II.2) was
vaccinated with live BCG at birth and presented axillary
BCG adenitis at age 3 mo. Both responded well to an-
tibiotics. The proband and his brother are now 10 and
9 years old, respectively, and are healthy, with no current
treatment. Another sibling (D.II.4) was vaccinated with
live BCG at birth and presented axillary BCG adenitis
12 mo later. She was successfully treated with antibiotics
and by surgical excision. At age 15 mo, she presented
with Salmonella type C gastroenteritis. At age 2 years 6
mo, she developed occipital lymphadenitis due to M.
tuberculosis. She was successfully treated with antibi-
otics but suffered a relapse at age 4 years. She is now 5
years old and well, with no antibiotic treatment. The
three other siblings were vaccinated with BCG, with no
adverse effect, and are currently healthy at ages 6, 3,
and 1 years.
Kindred E.—The parents are first cousins, originating
from and living in Saudi Arabia. The proband (E.II.2)
was vaccinated with live BCG at birth and presented
with disseminated BCG infection 8 mo later. After sur-
gical excision, she was treated with antibiotics and INFg.
She did not respond to treatment and later died of dis-
seminated infection at age 2 years. Her adenitis biopsy
showed tuberculoid lymphadenitis with poorly formed
granuloma and numerous visible acid-fast bacilli. Her
brother (E.II.1) was vaccinated with live BCG, with no
adverse effect.
Kindred F.—The parents are first cousins, originating
from and living in Saudi Arabia. The third sister (F.II.3)
was vaccinated with BCG at birth and presented with
disseminated BCG infection 3 mo later. She also suffered
from Salmonella adenitis. She was treated with antibi-
otics for a total of 18 mo. She remained well, with no
treatment, for 8 years. At age 11 years, she developed
meningoencephalitis. Unfortunately, this disease proved
fatal, and the causal microorganism was not isolated.
Her sister (F.II.4) was vaccinated with BCG at birth and
presented with disseminated BCG infection a few
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months later. She was successfully treated with antibi-
otics. She is now 11 years old and well, with no antibiotic
treatment. The proband (F.II.5) was not vaccinated with
BCG at birth. She developed disseminated M. chelonae
infection at age 3 years. She did not respond to treatment
and died of disseminated infection at 5 year of age. She
also presented Salmonella (group B) adenitis at age 3
years. Two other siblings were vaccinated with BCG,
with no adverse effects, and are currently healthy at ages
16 and 13 years. The other three children were not vac-
cinated and are currently healthy at ages 5, 2, and 1
year. Our study was done in compliance with institu-
tional requirements, and informed consent was obtained
from each patient’s family.
Cell Culture
Epstein-Barr virus–immortalized lymphoblastoid (EBV-
B) cell lines were cultured in Roswell Park Memorial In-
stitute (RPMI) 1640 (GibcoBRL) supplemented with 10%
heat-inactivated pooled fetal-calf serum (GibcoBRL).
They were incubated in 24-well plates at a concentration
of cells/ml with M phorbol-12,13-dibuty-6 71# 10 10
rate (PDBu) (Sigma) for 18 h. EBV-B cell lines derived
from a healthy individual and from a patient previously
diagnosed with IL12 deficiency (Altare et al. 1998c) were
used as a positive control (C) and as a negative control
(C), respectively. Whole-blood cells were cultured in
RPMI 1640 (GibcoBRL) in 24-well plates. The cells were
infected with live BCG (M. bovis BCG, Pasteur substrain)
either at a 20:1 multiplicity of infection alone or in the
presence of IFNg (5,000 IU/ml) or recombinant IL12p70
(20 ng/ml), for a period of 12 or 72 h.
Enzyme-Linked Immunosorbent Assay (ELISA)
Cell-culture supernatants were assayed for cytokines
by ELISA, by use of matched antibody pairs according
to the manufacturer’s suggestions. ELISA reagents for
human IL12p70 and IL12p40 (R&D Systems), TNFa
(CLB), and IFNg (CLB) were used. Optical density was
determined for each well, at 490 nm for IL12p70 and
at 450 nm for IL12p40, TNFa, and IFNg, by use of
an automated MR5000 ELISA reader (Dynatech). The
detection limits of the assays were 0.625 pg/ml for
IL12p70, 31.2 pg/ml for IL12p40, 1.4 pg/ml for TNFa,
and 5 pg/ml for IFNg.
RNA Extraction and cDNA Synthesis
Total RNA was isolated from EBV-B cell72# 10
lines, with RNAzol (Biogenesis) and chloroform iso-
amylalcohol (Sigma). RNA was reverse transcribed by
oligo (dT) with Superscript II reverse transcriptase
(GibcoBRL), to produce the first-strand cDNA. In brief,
5 mg of total RNA suspended in RNase-free water was
added to 20 ml of a reaction mixture consisting of 12.5
mM Tris-HCl, 0.75 mM MgCl2, 75 mM KCl, 5 mM
DTT, and 0.5 mM each dNTP. After an initial incubation
for 5 min at 42C, 200 U of Superscript II reverse tran-
scriptase was added. The reaction was continued for 60
min at 42C and then was terminated by heating at 70C
for 10 min. The single-stranded cDNA was then stored
at 20C.
PCR Amplification
PCR amplification was performed with 1 ml of cDNA
template and 50 ml of a reaction mixture consisting of
10 mM Tris-HCl, 2 mM MgCl2, 50 mM KCl, 0.2 mM
each dNTP, and 1.25 U Taq DNA polymerase (Applied
Biosystems). The primers used to amplify the coding
regions of the IL12B and IL12A cDNAs (used at a con-
centration of 0.1 mM) were as follows: IL12B, sense (5′-
ggC CCA gAg CAA gAT gTg TC-3′) and antisense (5′-
Tgg gTC TAT TCC gTT gTg TC-3′); and IL12A, sense
(5′-TCA CCg AgA AgC TgA TgT Ag-3′) and antisense
(5′-Tgg ATg TAA TAg TCC CAT CC-3′). The IL12B
and IL12A cDNA coding regions were amplified by PCR
under the following conditions: initial denaturation at
94C for 5 min; followed by 40 cycles at 94C for 30
s, 55C for 1 min, and 72C for 90 s; and a final elon-
gation step at 72C for 10 min.
Genomic DNA Extraction and Amplification
Human genomic DNA was isolated from 72# 10
EBV-B cells. The cells were lysed in extraction buffer (10
mM Tris, 0.1 M EDTA, 0.5% SDS, and 10 mg protein-
ase K/ml) overnight at 37C and were extracted with
phenol and chloroform, and the DNA was precipitated
in ethanol. PCR amplification was performed using 100
ng genomic DNA as the template and 50 ml of a reaction
mixture consisting of 10 mM Tris-HCl, 2 mM MgCl2,
50 mM KCl, 0.2 mM each dNTP, and 1.25 U Taq DNA
polymerase (Applied Biosystems). The primers and con-
ditions used for PCR amplification of the coding exons
of IL12B, including the flanking intron sequences, are
available on request.
Sequencing
Amplified PCR products were analyzed by gel elec-
trophoresis in a 1% agarose gel and were purified by
centrifugation through Sephadex G-50 Superfine resin
(Amersham) on filter plates multiscreen MAHV-N45
(Millipore). A series of nested primers was used for se-
quencing (available on request). PCR products were se-
quenced by dideoxynucleotide termination with the
BigDye terminator kit (Applied Biosystems). Sequences
were analyzed on an ABI Prism 377 apparatus (Applied
Biosystems).
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Northern Blotting
Total RNA (10 mg) was separated by electrophoresis
in a denaturing 1% agarose gel containing 4.5% for-
maldehyde at 55 V for 3 h, was transferred to a nitrocellu-
lose membrane (Dupont-NEN), and was probed with
[32P]-labeled IL12B or GAPDH probes consisting of 1-
kb fragments of wild-type cDNA PCR products. The
probes were produced by random priming. The primers
used to amplify IL12B were sense (5′-ggC CCA gAg CAA
gAT gTg TC-3′) and antisense (5′-Tgg gTC TAT TCC gTT
gTg TC-3′). Transfer and hybridization were performed
as described elsewhere (Jouanguy et al. 1996).
Southern Blotting
Genomic DNA (20 mg) was digested with BamHI
(GibcoBRL), was run on a 0.6% agarose gel at 55 V
for 4 h, was blotted onto a nitrocellulose membrane
(Dupont-NEN), and was hybridized with a [32P]-labeled
IL12B probe consisting of a 1-kb fragment of a wild-
type cDNA PCR product. The primers used to amplify
IL12B were sense (5′-ggC CCA gAg CAA gAT gTg TC-
3′) and antisense (5′-Tgg gTC TAT TCC gTT gTg TC-
3′). Transfer and hybridization were performed as de-
scribed elsewhere (Altare et al. 1998c).
Polymorphic Marker Genotyping
Polymorphic CA repeats located in a 10,567-Mb in-
terval around IL12B are available from Ge´ne´thon. They
were amplified, [33P]-labeled, and subjected to gel elec-
trophoresis as described elsewhere (Jouanguy et al.
1996). Three single-nucleotide polymorphisms (SNPs) in
IL12B (1356G/T, 36492A/G, and 1146 C/A) were
genotyped by sequencing.
Dating of Mutations
We estimated the age of the two founder mutations
(g.48282_856-854del and g.315_316insA) by a like-
lihood method that we recently developed (E.G. and
L.A., unpublished data). This method assumes that the
affected individuals are descended from a common an-
cestor in whom the mutation was introduced n gener-
ations ago. The method estimates n on the basis of the
size of the haplotype shared by patients on each side of
the disease locus, D, by a maximum-likelihood ap-
proach. The likelihood expression is based on two func-
tions: (1) the probability that no crossing-over occurred
during n generations between D and a marker x located
at a recombination fraction from D, a probabilityvx
denoted as , and (2) the probability thatnS(x)p (1 v )x
a crossing-over occurred in the xth interval between
markers and x located at recombination fractionsx 1
and (with ), a probability denoted asv v v ! vx1 x x1 x
. The method also takes into accountS(x 1) S(x)
marker-allele frequencies, allowing for the possibility that
recombination occurs not in the xth interval but in the
( )th or the ( )th interval, with a chromosomex 1 x 2
carrying the same allele or alleles as the ancestral hap-
lotype at the ( )th or ( )th marker. Marker-allelex 1 x 2
frequencies were estimated from a sample of 32 subjects
of Indian origin (g.48282_856–854del mutation) and
25 subjects of Arabian origin (g.315_316insA mutation).
The 95% confidence interval (95%CI) of n was obtained
by a Bayesian approach, as proposed by Piccolo et al.
(1996). Large simulation studies have shown that this
method provides reliable estimates of n and have high-
lighted the importance of taking into account marker-
allele frequencies in the likelihood expression (E.G. and
L.A., unpublished data). Since the genetic distances avail-
able for closely linked markers are generally not very ac-
curate, rates of recombination between markers were
computed using both the overall genetic length of the
haplotype and the physical distances between markers.
Since the genetic and physical distances between D5S410
and D5S422, the two extreme markers of the haplotype,
are 7.1 cM (Ge´ne´thon Map) (Dib et al. 1996) and 10.567
Mb, respectively, as calculated by BLAST human-genome
searches, the correspondence between genetic and phys-
ical distances over the whole region was estimated to be
0.672 cM for 1 Mb. Recombination fractions between
the different markers and IL12B were then computed
from genetic distances, by means of the Kosambi mapping
function.
Results
Impaired Secretion of IL12 in EBV-B Cells
PDBu-activated EBV-B cell lines are known to secrete
detectable levels of IL12p40 and IL12p70 (Trinchieri
1998). We therefore tested cells derived from 70 patients
with idiopathic BCG or NTM disease, for IL12 secre-
tion. Three activated cell lines (from patients B.II.3,
C.II.3, and D.II.4) secreted no IL12p40 and no IL12p70
into the supernatant, as detected by ELISA (fig. 2A).
Both IL12p70 and IL12p40 were detected in the super-
natant of PDBu-activated control B cells (i.e., C) (fig.
2A). As expected, neither IL12p40 nor IL12p70 was
detected in the supernatant of PDBu-activated EBV-B
cells from a child previously reported to have IL12p40
deficiency (i.e., C; A.II.1) who carried a large homozy-
gous loss-of-function deletion (g.48282_856–854del)
in IL12B (Altare et al. 1998c). Inducible TNFa levels
confirmed that EBV-B cells from the two controls and
from patients B.II.3, C.II.3, and D.II.4 were fully acti-
vated by PDBu (fig. 2A). Defective IL12 production was
observed in EBV-B cells derived from three affected sib-
lings from kindreds C (C.II.2) and D (D.II.1 and D.II.2)
(data not shown). EBV-B cells were not available from
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Figure 2 Impaired production of IL12. A, Production of IL12p70, IL12p40, and TNFa, by PDBu-stimulated EBV-B cells from a healthy
positive control (C) and a negative control (C; A.II.1) (both of whom had previously been reported by Altare et al. [1998c]) and from
patients (B.II.3, C.II.3, and D.II.4). Supernatants were harvested after 18 h of activation, for cytokine quantification by ELISA. The results are
the mean  SDs of two experiments. B, Production of IL12p70, IL12p40, and TNFa, by whole-blood cells from a healthy positive control
(C) and from patient D.II.4, either unstimulated (Medium) or stimulated with BCG plus IFNg. Supernatants were harvested after 12 h of
activation. C, Production of IFNg by whole-blood cells from healthy positive control (C) and from patient D.II.4, either unstimulated (Medium)
or stimulated with BCG alone or with BCG plus recombinant IL12p70. The supernatants were harvested after 72 h of activation, for cytokine
quantification by ELISA.
affected siblings B.II.1 and C.II.1. These results suggest
that at least six patients, from kindreds B–D, had IL12
deficiency.
Impaired Secretion of IL12 in Blood Cells
To validate the results obtained with EBV-B cells, we
measured the production of IL12p40 and IL12p70 by
whole-blood cells from patient D.II.4; the cells were ei-
ther unstimulated or stimulated with live BCG plus IFNg
(fig. 2B). Neither IL12p70 nor IL12p40 was detected by
ELISA. In contrast, both IL12p70 and IL12p40 were
detected in the control-cell supernatant (i.e., C) (fig.
2B). Inducible TNFa levels confirmed that blood cells
from the control and patient D.II.4 were fully activated
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Figure 3 IL12B mutant alleles. A, Schematic representation of structural organization of coding region of wild-type (WT) IL12B gene.
Exons I and VIII are not translated. Intrachain disulfite bounds and amino acids essential for dimerization with IL12p35 are indicated by the
single-letter amino acid code. The positions of the two mutations found in IL12-deficient patients are also indicated. B, Schematic representation
of coding region of two mutant IL12B alleles. Gray regions correspond to stretches of new amino acids resulting from the frameshift mutation.
(fig. 2B). Similar results were obtained if cells were stim-
ulated with BCG alone (not shown). In a previous ex-
perimental study, we had shown that neither IL12p40
nor IL12p70 was detectable in the supernatant of sim-
ilarly activated blood cells derived from patient A.II.1
(i.e., C) (Altare et al. 1998c). We therefore measured
IFNg production by blood cells from a control (i.e., C)
and from patient D.II.4, the cells being either unsti-
mulated or stimulated by live BCG or BCG plus IL12p70
(fig. 2C). The addition of recombinant exogenous
IL12p70 led to an increase in IFNg production in the
patient’s blood cells, to almost normal levels, in response
to BCG challenge (fig. 2C). This experiment shows that
the lack of detectable IL12 accounts for the poor pro-
duction of IFNg.
A Large Deletion in IL12B
A cDNA was synthesized from mRNA derived from
the EBV-B cells of patient B.II.3. This cDNA was used
to amplify and sequence the IL12A and IL12B coding
regions. A large frameshift deletion of 373 nt was detected
between positions 482 and 856 in IL12B (not shown).
The sequence of the coding region of the IL12A gene
displayed no mutation. Genomic DNA was used as the
template for PCR amplification of the eight IL12B exons
and flanking intron regions. A homozygous 4.6-kb frame-
shift deletion mutation encompassing coding exons V and
VI was identified and designated “48282_856–854del”
(fig. 3) (Dunnen and Antonarakis 2000). This deletion is
identical to that found in the Pakistani patient (A.II.1)
who elsewhere had been reported to have IL12p40 de-
ficiency (Altare et al. 1998c) and was not found in 174
unrelated healthy controls from the Indian subcontinent
(59 of whom were from the Gujarat region). This indi-
cates that the frequency of this deletion can be estimated
(with a P 1.95) to be !0.009. By northern blot analysis,
IL12B transcripts were not detected in B.II.3 and A.II.1
(i.e., C) EBV-B cells, in contrast to those of the positive
control (not shown). This mutation results in the loss of
167 of the original 328 amino acids and in the addition
of 45 new amino acids to the COOH-terminal region of
the mature polypeptide. In a previous experimental study,
we had demonstrated that the g.48282_856-854del
mutation is a loss-of-function mutation, by transfecting
a B cell line from the patient with the mutant and a wild-
type IL12B allele (Altare et al. 1998c). As in kindred A
(Altare et al. 1998c), we showed by Southern blot anal-
ysis that patient B.II.3 was homozygous—and that her
healthy brother and mother were heterozygous—for the
deletion, strongly suggesting that the deletion is recessive
in kindred B (not shown). DNA from the father and
from the first, deceased child (B.II.1) was not available
for analysis.
A Small Insertion in IL12B
Sequencing of the coding region of the IL12B cDNA
from patients C.II.3 and D.II.4 revealed the insertion of
an adenosine between positions 315 and 316 (not
shown). No mutation was observed in the sequence of
the coding region of IL12A. Genomic amplification and
sequencing of the IL12B exon III confirmed that the
mutation (designated “g.315_316insA”) was homozy-
gous (fig. 3). This mutation was not found in 115 Ara-
bian healthy unrelated controls analyzed (73 of whom
were from the Arabian Peninsula). This indicates that
the frequency of this insertion can be estimated (with a
P 10.95) to be !0.012. The frameshift results in a pre-
mature stop codon at nucleotide positions 342–344. By
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Figure 4 High-resolution map of IL12B locus. A, Physical map of IL12B region on chromosome 5q33. The physical distances (in Mb)
between IL12B and microsatellite markers were obtained from BLAST. B, Genomic organization of human IL12B gene and location of intragenic
SNPs. White boxes indicate coding exons; gray boxes indicate untranslated exons. Translation initiation and termination codons are indicated.
Arrows indicate positions of intragenic SNPs (1356, 36492, and 1146).
northern blot analysis, IL12B transcripts were not de-
tected in PDBu-stimulated EBV-B cells from patients
C.II.3 and D.II.4. IL12B transcripts were detected in
PDBu-stimulated EBV-B cells from a control (i.e., C)
(not shown). This mutation results in the loss of 223 of
the original 328 amino acids and in the addition of 9
new C-terminal amino acids. The encoded protein lacks
all the amino acids shown by crystallography to be es-
sential for p40 dimerization with p35 (fig. 3) (Yoon et
al. 2000). Healthy relatives were found to be either het-
erozygous for the g.315_316insA mutant allele or ho-
mozygous for a wild-type allele. These data strongly sug-
gest that the g.315_316insA mutation accounts for the
lack of detectable p40 and p70 and is a loss-of-function
recessive mutation.
IL12 Deficiency in Other Kindreds
We next sequenced IL12B exons in 16 patients se-
lected from 4 kindreds from the Indian subcontinent
and from 10 kindreds from the Arabian Peninsula, for
whom EBV-B cells were not available. We identified
four patients (E.II.2, F.II.3, F.II.4, and F.II.5) from two
new kindreds (E and F) from Saudi Arabia that carried
the homozygous mutation g.315_316insA (fig. 1). No
mutations were found in the other patients. Parents and
healthy siblings from kindreds C–F were heterozygous
for g.315_316insA (fig. 1). DNA from the first deceased
sibling (B.II.1) of kindred B and from the healthy sib-
lings (F.II.1, F.II.2, F.II.6, F.II.7, and F.II.8) of kindred
F were not available for analysis. No other mutations
were found in the coding region of IL12B. In total,
nine patients from four kindreds (C–F) from Saudi Ara-
bia were found to be homozygous for an identical loss-
of-function IL12B frameshift insertion (g.315_316insA)
(fig. 1).
A Founder Effect Accounts for the Recurrence of
These Mutations
Polymorphic markers encompassing the IL12B gene
on 5q31.1-5q33, including flanking dinucleotide re-
peats (D5S410, D5497, SD5S662, D5S487, D5S2016,
D5S412, D5S1971, D5S2112, D5S2060, D5S2047,
D5S2118, and D5S422) and intragenic SNPs (1356
G/T, 36492 A/G, and 1146 C/A) were genotyped in
all patients (fig. 4). A 3.6-Mb homozygous haplotype
defined by the three intragenic SNPs (not shown) and
by seven microsatellites (D5S662–D52060) is shared
by all affected siblings from kindreds A and B (who
are homozygous for the g.48282_856–854del mu-
tation) (fig. 5). Patients from kindreds C–F (homo-
zygous for the g.315_316insA mutation) share a
0.516-Mb common homozygous haplotype defined by
the three intragenic SNPs (not shown) and two mi-
crosatellites (D5S412 and D5S1971) (fig. 5). These
data strongly suggest that each mutation results from
a founder event. We developed a new mutation-dating
method to date both the closest ancestor common to
all patients from kindreds A and B and the closest
ancestor to all patients from kindreds C–F (E.G. and
L.A., unpublished data). Indeed, methods described
elsewhere (Guo and Xiong 1997; McPeek and Strahs
1999; Slatkin and Rannala 2000) do not apply to very
small numbers of kindreds. For the g.48282_856–
854del mutation, the estimated number of generations
since the appearance of the common ancestor is 29
(95%CI 9–115). If it is assumed that a generation is
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Figure 5 Haplotypes encompassing IL12B in patients with IL12 deficiency. Markers encompassing IL12B, with physical distance (Mb)
and recombination rate (v), are shown. Physical distance was obtained from BLAST; the recombination rate was estimated by use of the
correspondence of .672 cM for 1 Mb, over the whole region, and use of the Kosambi mapping function (see the “Dating of Mutations”
subsection). The ancestral haplotypes shared by kindreds A and B, from the Indian subcontinent, is indicated by dark-gray shading; the ancestral
haplotype shared by kindreds C–F, from Saudi Arabia, is indicated by intermediate-gray shading; and the ancestral haplotype shared by a subset
of kindreds is indicated by light-gray shading.
∼24 years, then the g.48282_856–854del mutation
in IL12B is ∼700 years old (95%CI 216–2,760). For
the g.315_316insA mutation, the estimated number
of generations is 47 (95%CI 22–110), indicating that
this mutation in IL12B is ∼1,100 years old (95%CI
528–2,640).
Discussion
We report herein 12 patients from five new kindreds with
complete IL12 deficiency associated with IL12B muta-
tions. Our study illustrates that, although rare, this hu-
man cytokine gene disorder is not limited to the single
patient who has been described elsewhere (Altare et al.
1998c). Twelve of the 13 patients with IL12 deficiency
were found to suffer from mycobacteriosis, and 5 were
found to suffer from salmonellosis, which was the sole
clinical manifestation in 1 child. Despite an overall better
clinical outcome than that had by patients with complete
IFNgR deficiency, interfamilial heterogeneity was ob-
served. In one kindred from India, we found a large
deletion that was previously reported in a kindred from
Pakistan (Altare et al. 1998c), whereas, in four kindreds
from Saudi Arabia, we identified a new recessive loss-
of-function IL12B small insertion. Each rare mutation
resulted from a founder effect in either the Indian sub-
continent (large deletion) or the Arabian Peninsula
(small insertion), and, by a new method, we were able
to date those original mutation events to ∼700 and
∼1,100 years ago, respectively.
This study confirms that IL12 deficiency is principally
associated with infectious diseases caused by Mycobac-
teria (table 1). All but one of the patients reported here
have had at least one episode of mycobacterial infection.
All children inoculated with live BCG vaccine developed
clinical infection, as did the previously reported IL12-
deficient patient (Altare et al. 1998c). One patient who
was not inoculated with BCG developed NTM infection
(a fast-growing species, M. chelonae). One child with
BCG infection subsequently developed M. tuberculosis
adenitis. Most patients with IL12Rb1 deficiency are sus-
ceptible to BCG (Altare et al. 1998a; de Jong et al. 1998;
Verhagen et al. 2000), and two children who were ap-
parently resistant to BCG developed M. chelonae (Aksu
et al. 2001) and M. tuberculosis (Altare et al. 2001)
infections. Another NTM, M. avium, which was de-
tected in IL12Rb1-deficient patients not previously in-
oculated with BCG (de Jong et al. 1998; Verhagen et
al. 2000; Sakai et al. 2001), has not, to date, been di-
agnosed in the series of IL12-deficient patients whom
we studied. Experimental studies have shown that IL12
is essential for protective immunity against Mycobacte-
ria in mice. Animals with disrupted IL12B genes are
highly susceptible to BCG (Cooper et al. 1997; Wake-
ham et al 1998), M. avium (Doherty and Sher 1998;
Silva et al. 2001), and M. tuberculosis (Magram et al.
1996). Our results extend these observations, highlight-
ing the crucial role that IL12 plays in antimycobacterial
immunity in mice and humans. Clinically, IL12 defi-
ciency should be considered in the genetic diagnosis of
patients with BCG or NTM severe diseases. Further
studies are required to investigate the role that rare and
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frequent IL12B mutations play in susceptibility to tu-
berculosis in the general population (Abel and Casanova
2000).
Together with our previous report (Altare et al.
1998c), this study suggests that the course of mycobac-
terial infection in patients with complete IL12 deficiency
is less severe than that in patients with complete IFNgR
deficiency (Jouanguy et al. 1996; Newport et al. 1996;
Pierre-Audigier et al. 1997; Dorman and Holland 1998;
Roesler et al. 1999; Cunningham et al. 2000; Jouanguy
et al. 2000; Allende et al. 2001). Only 5 of the 13 IL12-
deficient patients (aged 2–11 years) died of infection;
the 8 survivors (aged 3–12 years) responded well to
antibiotics and are now well and not currently taking
medication (i.e., for 2–9 years have not undergone treat-
ment). Granuloma formation is preserved but often
multibacillary in patients with IL12 deficiency, whereas
patients with complete IFNgR deficiency are not able
to form mature granulomas. However, there is consid-
erable interfamilial heterogeneity in terms of outcome.
Nine patients have presented disseminated mycobacteri-
al infection, which has proved fatal in four cases,
whereas, in three children from the same kindred, BCG
infection was clinically limited to the draining lymph
nodes. Accordingly, the clinical outcome of IL12Rb1
deficiency also differs greatly between patients, with two
deaths reported (at age 5–8 years) and 10 survivors
(aged 7–31 years) well and not currently taking medi-
cation (Altare et al. 1998a; de Jong et al. 1998; Ver-
hagen et al. 2000; Aksu et al. 2001; Altare et al. 2001;
Sakai et al. 2001).
Five patients have presented clinical Salmonella in-
fection, as did the IL12-deficient patients described by
Altare et al. (1998c) and 6 of 12 IL12Rb1-deficient pa-
tients reported elsewhere (Altare et al. 1998a; de Jong
et al. 1998; Verhagen et al. 2000). This is a well-known
feature of the syndrome of Mendelian susceptibility to
mycobacterial disease (Levin et al. 1995; Casanova et
al. 1996). Other severe infections caused by Listeria
monocytogenes (Roesler et al. 1999), Histoplasma cap-
sulatum (Jouanguy et al. 1999), and viruses (Dorman
et al. 1999; Cunningham et al. 2000; Uzel et al. 2000),
which elsewhere have been reported in patients with
IFNgR deficiency, were not diagnosed in patients with
IL12 or IL12R deficiency; however, we report, for the
first time, a case of clinical N. asteroides infection in a
patient with an impaired IL12-IFNg axis. It is difficult
to determine whether there is a causal relationship be-
tween impaired IL12-mediated immunity and nocar-
diosis. Such a relationship is probable, however, given
the considerable biochemical and phylogenetic similar-
ity between Mycobacterium and Nocardia, which form,
together with Corynebacterium, a monophyletic taxon
of mycolic acid–containing acid-fast gram-positive bac-
teria (Embley and Stackebrandt 1994).
A novel heterodimeric cytokine, interleukin-23 (IL23),
has recently been described (Oppmann et al. 2000). This
cytokine consists of the p40 subunit of IL12 and a novel
p19 subunit, encoded by a gene mapping to 12q13. IL23
is produced by activated mature dendritic cells and in-
duces IFNg production by memory T lymphocytes in
humans and in mice. The patients with IL12p40 defi-
ciency described herein therefore probably suffer not only
from IL12 deficiency but also from IL23 deficiency. Fur-
ther studies with hIL23-specific antibodies are necessary
to investigate whether this is indeed the case. If IL23
deficiency is established in these patients, it will be
important to discriminate between the specific contri-
butions of IL12 and IL23 deficiencies to the devel-
opment of mycobacterial disease in patients with
IL12B mutations. IL12p35-deficient mice have a phe-
notype milder than do IL12p40-deficient mice, in
terms of vulnerability to Leishmania major (Mattner
et al. 1996) and to Cryptococcus neoformans (Decken
et al. 1998), suggesting that IL23 may perhaps con-
tribute to protection against mycobacteria. The iden-
tification of IL12p35-deficient patients with a milder
phenotype than that of IL12p40-deficient patients
would support this hypothesis.
Only two IL12B mutant alleles accounted for IL12
deficiency in the six kindreds identified. A large deletion
was found in patients from the Indian subcontinent, and
a small insertion was found in patients from the Arabian
Peninsula. The Pakistani child and the Indian child, both
originating from the northern region of the Indian sub-
continent, presented a large deletion (g.48282_856–
854del) encompassing exons V and VI (Altare et al.
1998c). A 3.6-Mb homozygous haplotype encompassing
IL12B is shared by the two patients, implying that a
founder effect is involved. The g.315_316insA mutation,
which was found in four unrelated kindreds from Saudi
Arabia, has not previously been described and the 0.516-
Mb homozygous haplotype shared by the four kindreds
is also strongly suggestive of a founder effect. These are
the first two examples of founder effects in genetic defects
of the IL12-IFNg axis, which predispose the individual
to mycobacterial disease. The closest common ancestor
carrying the founder allele in each region was dated by
a new method (E.G. and L.A., unpublished data), which
was developed for use with very small numbers of kin-
dreds. The common ancestor of patients carrying the In-
dian deletion was estimated to have lived ∼700 years ago,
whereas the common ancestor of patients carrying the
Saudi Arabian insertion was estimated to have lived
∼1,100 years ago. The two IL12B mutant alleles are
probably rare (frequency ! .01) in the respective popu-
lations, because they were not found in all healthy in-
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dividuals genotyped. Novel homozygous cases are, how-
ever, likely to be identified in the future, particularly in
more-specific regions (e.g., northern India–Pakistan and
Saudi Arabia). A direct clinical implication of this study
is that well-defined IL12B mutations should be sought
as a matter of priority in patients with mycobacteriosis
and salmonellosis who originate from either the Indian
subcontinent or the Arabian Peninsula.
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